Data from Additional Clinical Studies on Tumor-Infiltrating Lymphocyte Therapy
February 16th 2023Shared insight from Amod Sarnaik, MD, and Krishna Komanduri, MD, on the halted DELTA-1 clinical trial of ITIL-168 in melanoma, followed by a focused discussion of SITC 2022 data on emerging TIL design and manufacturing strategies.
An Overview on Tumor-Infiltrating Lymphocyte Therapy for Solid Tumors
February 2nd 2023Expert perspectives on the mechanism of action behind tumor-infiltrating lymphocyte (TIL) therapy and how it might address existing unmet needs in the treatment of solid tumors, including melanoma and non–small cell lung cancer.
Rugo Summarizes Developments With Ribociclib and ADCs in HR-Positive Breast Cancer
December 26th 2022Dr Rugo discusses overall survival in the TROPiCS-02 trial, post-progression treatments after ribociclib and endocrine therapy in the MONALEESA-2, MONALEESA-3, and MONALEESA-7 studies, and what the AMALEE trial indicates about optimal doses of ribociclib in hormone receptor–positive breast cancer.
177Lu-FAP-2286 Displays Preliminary Antitumor Activity in Advanced or Metastatic Solid Tumors
Lutetium-177-FAP-2286 produced preliminary evidence of antitumor activity with a manageable safety profile in patients with advanced or metastatic solid tumors, according to data from the phase 1/2 LuMIERE trial.
Camrelizumab/Rivoceranib Combo Significantly Improves Survival Over Sorafenib in Unresectable HCC
First-line treatment with camrelizumab plus rivoceranib resulted in a significant improvement in progression-free survival and overall survival compared with sorafenib in patients with unresectable hepatocellular carcinoma.
Advances in Breast and Gastrointestinal Cancers at ESMO 2022: Drs Rugo and Abou-Alfa
September 10th 2022OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Immunotherapy Combination Selection Is Driven by PD-L1 in Gastroesophageal Cancer
Andrew H. Ko, MD, discusses the multitude of treatment options for patients with gastroesophageal cancer, emerging combinations in hepatocellular carcinoma, and how HER2 expression can drive therapy decisions in colorectal cancer.
Understanding the Role of pCR in Early-Stage TNBC Opens Doors for Tailored Treatment
As ongoing research efforts are shifting further into personalized care, Hope S. Rugo, MD, FASCO discusses how pathologic complete response and the predictive value of residual cancer burden scoring are becoming a pivotal end point for the changing triple-negative breast cancer landscape.
Rivoceranib Elicits Promising Responses in Adenoid Cystic Carcinoma
The oral VEGFR2 TKI rivoceranib demonstrated an objective response rate by investigator assessed RECIST 1.1 criteria of 15.1% and a disease control rate of 64.4% for patients with recurrent or metastatic adenoid cystic carcinoma.
Frontline Therapy Advances Are Current Focus in SCLC and NSCLC
April 18th 2022Lung cancer management methods are rapidly evolving to encompass immunotherapy in the frontline setting and approved second-line options with tyrosine kinase inhibitors and monoclonal antibodies in non–small cell lung cancer, as well as treatment advances in first- and second-line small cell lung cancer.
Cilta-cel Offers Durable Option for Heavily Pretreated Multiple Myeloma
March 23rd 2022The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma, following 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Neoadjuvant Immunotherapy/Chemotherapy Combos Gain in Prominence for Early-Stage TNBC
Immunotherapy treatment for early-stage triple-negative breast cancer is enjoying a boom period, though there are still unanswered questions, particularly around the optimal chemotherapy backbone and patient selection.
UCSF Showcases Potentially Game-Changing Trials Across Multiple Myeloma Settings
Thomas G. Martin, MD, discusses some of the exciting clinical trials open at UCSF Helen Diller Family Comprehensive Cancer Center in multiple myeloma, especially for those in the relapsed/refractory setting.
Investigators Navigate the Complicated Treatment Landscape of Chemotherapy-Induced Neutropenia
January 19th 2022Advances in the treatment of solid tumors and hematologic malignancies have resulted in the development of thera-peutic regimens that can be administered at various points in a patient’s care.
Dr. Banerjee on the Rationale to Create a Supportive Mobile Health App for CAR T-Cell Therapy
December 23rd 2021Rahul Banerjee, MD, discusses the rationale to create a supportive mobile health companion app for CAR T-cell therapy recipients and their caregivers to use throughout the therapeutic process.